title: Naïve and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: implicatip6s for transmission and pathogenesis.
abstract: In vitro evidence suggests that memory CD4(+) cells are preferentially infected by human immunodeficiency virus type 1 (HIV-1), yet studies of HIV-1-infected individuals have failed to detect preferential memory cell depletion. To explore this paradox, we stimulated CD45RA+ CD4(+) (naïve) and CD45RO+ CD4(+) (memory) cells with antibodies to CD3 and CD28 and infected them with either CCR5-dependent (R5) or CXCR4-dependent (X4) HIV-1 isolates. Naïve CD4(+) cells supported less X4 HIV replication than their memory counterparts. However, naïve cells were susceptible to R5 viral infection, while memory cells remained resistant to infection and viral replication. As with the unseparated cells, mixing the naïve and memory cells prior to infection resulted in cells resistant to R5 infection and highly susceptible to X4 infection. While both naïve and memory CD4(+) subsets downregulated CCR5 expression in response to CD28 costimulation, only the memory cells produced high levels of the beta-chemokines RANTES, MIP-1alpha, and MIP-1beta upon stimulation. Neutralization of these beta-chemokines rendered memory CD4(+) cells highly sensitive to infection with R5 HIV-1 isolates, indicating that downregulation of CCR5 is not sufficient to mediate complete protection from CCR5 strains of HIV-1. These results indicate that susceptibility to R5 HIV-1 isolates is determined not only by the level of CCR5 expression but also by the balance of CCR5 expression and beta-chemokine production. Furthermore, our results suggest a model of HIV-1 transmission and pathogenesis in which naïve rather than memory CD4(+) T cells serve as the targets for early rounds of HIV-1 replication.
authors.affiliation: Division of Retrovirology, Walter Reed Army Institute for Research, Rockville, Maryland 20850, Bethesda, Maryland 20889, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Riley
authors.forename: B L
authors.initials: BL
authors.lastname: Levine
authors.forename: N
authors.initials: N
authors.lastname: Craighead
authors.forename: T
authors.initials: T
authors.lastname: Francomano
authors.forename: D
authors.initials: D
authors.lastname: Kim
authors.forename: R G
authors.initials: RG
authors.lastname: Carroll
authors.forename: C H
authors.initials: CH
authors.lastname: June
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology*; D001483:Base Sequence; D017252:CD3 Complex / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D019742:Chemokines, CC / Q000276:immunology; D017931:DNA Primers; D015658:HIV Infections / Q000276:immunology* / Q000635:transmission; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D007156:Immunologic Memory; D008562:Membrane Glycoproteins; D009244:NAD+ Nucleosidase / Q000276:immunology*; D015728:Receptors, HIV / Q000378:metabolism; D014779:Virus Replication / Q000276:immunology
chemical_list: D015703:Antigens, CD; D000943:Antigens, Differentiation; D017252:CD3 Complex; D019742:Chemokines, CC; D017931:DNA Primers; D008562:Membrane Glycoproteins; D015728:Receptors, HIV; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1